Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Boehringer Ingelheim to expand R&D and pharmaceutical manufacturing, ensuring the bulk of its medicines for U.S. patients will be produced in the U.S. RIDGEFIELD, Conn., Dec. 19, 2025 /PRNewswire/ -- ...

Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...

Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for IT and Global Business Services effective 1 February 2026 Boehringer Ingelheim announced today ...

Boehringer Ingelheim has secured FDA approval for its PDE4 inhibitor nerandomilast (Jascayd) for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. Nerandomilast ...

Boehringer Ingelheim (BI) has secured an exclusive, worldwide licence from Kyowa Kirin for a pre-clinical, first-in-class small molecule targeting fibro-inflammatory diseases, an area that includes ...

After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well. Boehringer will pay AimedBio up to $991 million to license and develop ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company. The drug, ...

Aug 8 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Boehringer Ingelheim's drug for patients with a type of advanced lung cancer who have received prior treatment.

Please provide your email address to receive an email when new articles are posted on . The companies will work together to develop sustained-release ophthalmic therapies. The deal has a potential ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral BI 1815368 from Boehringer Ingelheim aims to ...